Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Ensysce Biosciences (ENSC) Net Margin (2020 - 2025)

Historic Net Margin for Ensysce Biosciences (ENSC) over the last 6 years, with Q3 2025 value amounting to 756.26%.

  • Ensysce Biosciences' Net Margin fell 7756100.0% to 756.26% in Q3 2025 from the same period last year, while for Sep 2025 it was 244.49%, marking a year-over-year decrease of 652000.0%. This contributed to the annual value of 153.3% for FY2024, which is 3230900.0% up from last year.
  • Ensysce Biosciences' Net Margin amounted to 756.26% in Q3 2025, which was down 7756100.0% from 126.39% recorded in Q2 2025.
  • Over the past 5 years, Ensysce Biosciences' Net Margin peaked at 19.36% during Q3 2024, and registered a low of 3855.62% during Q2 2022.
  • For the 5-year period, Ensysce Biosciences' Net Margin averaged around 849.65%, with its median value being 455.88% (2023).
  • As far as peak fluctuations go, Ensysce Biosciences' Net Margin tumbled by -36451500bps in 2022, and later surged by 33997400bps in 2023.
  • Quarter analysis of 5 years shows Ensysce Biosciences' Net Margin stood at 662.88% in 2021, then skyrocketed by 42bps to 385.21% in 2022, then tumbled by -77bps to 680.4% in 2023, then skyrocketed by 60bps to 273.42% in 2024, then tumbled by -177bps to 756.26% in 2025.
  • Its Net Margin was 756.26% in Q3 2025, compared to 126.39% in Q2 2025 and 147.42% in Q1 2025.